Tyvaso FDA Approval History
Last updated by Judith Stewart, BPharm on June 1, 2022.
FDA Approved: Yes (First approved July 30, 2009)
Brand name: Tyvaso
Generic name: treprostinil
Dosage form: Inhalation Solution
Company: United Therapeutics Corporation
Treatment for: Pulmonary Arterial Hypertension
Tyvaso (treprostinil) is a prostacyclin mimetic used for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
- Tyvaso is indicated for the treatment of:
- Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with Tyvaso establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%).
- Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with Tyvaso establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%).
- Tyvaso is administered via the Tyvaso Inhalation System in 4 separate treatment sessions each day approximately 4 hours apart, during waking hours.
- Warnings and precautions include symptomatic hypotension, increased risk of bleeding, and bronchospasm.
- Common adverse reactions include cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, diarrhea, and syncope.
Development timeline for Tyvaso
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
